Exome Asset Management LLC Invests $1.50 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Exome Asset Management LLC bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 3rd quarter, Holdings Channel.com reports. The fund bought 45,600 shares of the company’s stock, valued at approximately $1,500,000.

Several other large investors also recently added to or reduced their stakes in the business. Cowen AND Company LLC increased its position in Tarsus Pharmaceuticals by 3.5% during the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after buying an additional 74,855 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after acquiring an additional 698,712 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Tarsus Pharmaceuticals by 7.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after acquiring an additional 77,825 shares during the last quarter. Ikarian Capital LLC lifted its holdings in Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after purchasing an additional 230,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock worth $27,494,000 after purchasing an additional 62,555 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TARS. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Finally, William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $52.50 on Friday. Tarsus Pharmaceuticals, Inc. has a one year low of $18.30 and a one year high of $54.44. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The business has a fifty day simple moving average of $44.72 and a 200 day simple moving average of $34.38. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -13.78 and a beta of 1.04.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.